Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Markella V. Zanni, M.D.

Co-Author

This page shows the publications co-authored by Markella Zanni and Kathleen Fitch.
Connection Strength

3.399
  1. Factors Associated with Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People with HIV on Antiretroviral Therapy. Clin Infect Dis. 2022 Mar 02.
    View in: PubMed
    Score: 0.247
  2. Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial. J Infect Dis. 2020 07 09; 222(Suppl 1):S63-S69.
    View in: PubMed
    Score: 0.221
  3. Correlates and Timing of Reproductive Aging Transitions in a Global Cohort of Midlife Women With Human Immunodeficiency Virus: Insights From the REPRIEVE Trial. J Infect Dis. 2020 07 09; 222(Suppl 1):S20-S30.
    View in: PubMed
    Score: 0.221
  4. Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of central coordination. HIV Res Clin Pract. 2020 02; 21(1):11-23.
    View in: PubMed
    Score: 0.216
  5. Sex Differences in Subclinical Coronary Atherosclerotic Plaque Among Individuals With HIV on Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2018 08 01; 78(4):421-428.
    View in: PubMed
    Score: 0.193
  6. Epicardial adipose tissue volume and cardiovascular risk indices among asymptomatic women with and without HIV. Antivir Ther. 2018; 23(1):1-9.
    View in: PubMed
    Score: 0.185
  7. Sex Differences in Select Non-communicable HIV-Associated Comorbidities: Exploring the Role of Systemic Immune Activation/Inflammation. Curr HIV/AIDS Rep. 2017 12; 14(6):220-228.
    View in: PubMed
    Score: 0.184
  8. Proprotein Convertase Subtilisin/Kexin 9 Levels in Relation to Systemic Immune Activation and Subclinical Coronary Plaque in HIV. Open Forum Infect Dis. 2017; 4(4):ofx227.
    View in: PubMed
    Score: 0.183
  9. Aspartame Intake Relates to Coronary Plaque Burden and Inflammatory Indices in Human Immunodeficiency Virus. Open Forum Infect Dis. 2017; 4(2):ofx083.
    View in: PubMed
    Score: 0.177
  10. Follow YOUR Heart: development of an evidence-based campaign empowering older women with HIV to participate in a large-scale cardiovascular disease prevention trial. HIV Clin Trials. 2017 03; 18(2):83-91.
    View in: PubMed
    Score: 0.175
  11. Subclinical myocyte injury, fibrosis and strain in relationship to coronary plaque in asymptomatic HIV-infected individuals. AIDS. 2016 09 10; 30(14):2205-14.
    View in: PubMed
    Score: 0.169
  12. Reduced ovarian reserve relates to monocyte activation and subclinical coronary atherosclerotic plaque in women with HIV. AIDS. 2016 Jan 28; 30(3):383-93.
    View in: PubMed
    Score: 0.162
  13. 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. AIDS. 2014 Sep 10; 28(14):2061-70.
    View in: PubMed
    Score: 0.147
  14. Prevalence and Correlates of Electrocardiographic Abnormalities in Adults With HIV: Insights From the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). J Acquir Immune Defic Syndr. 2022 03 01; 89(3):349-359.
    View in: PubMed
    Score: 0.062
  15. Geographical Differences in the Self-Reported Functional Impairment of People with HIV and Associations with Cardiometabolic Risk. Clin Infect Dis. 2022 Feb 15.
    View in: PubMed
    Score: 0.062
  16. COVID-19 Vaccination Rates in a Global HIV Cohort. J Infect Dis. 2022 02 15; 225(4):603-607.
    View in: PubMed
    Score: 0.062
  17. Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial. Clin Infect Dis. 2021 12 06; 73(11):2009-2022.
    View in: PubMed
    Score: 0.061
  18. Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus. Open Forum Infect Dis. 2021 Dec; 8(12):ofab537.
    View in: PubMed
    Score: 0.061
  19. Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention. JAMA Netw Open. 2021 06 01; 4(6):e2114923.
    View in: PubMed
    Score: 0.059
  20. Corrigendum to: Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial. J Infect Dis. 2021 02 03; 223(2):352.
    View in: PubMed
    Score: 0.057
  21. Differential Plasma Protein Regulation and Statin Effects in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV-Infected Patients Utilizing a Proteomics Approach. J Infect Dis. 2020 08 17; 222(6):929-939.
    View in: PubMed
    Score: 0.056
  22. Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum. J Infect Dis. 2020 07 09; 222(Suppl 1):S31-S40.
    View in: PubMed
    Score: 0.055
  23. Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial. J Infect Dis. 2020 07 09; 222(Suppl 1):S8-S19.
    View in: PubMed
    Score: 0.055
  24. Measures of Adipose Tissue Redistribution and Atherosclerotic Coronary Plaque in HIV. Obesity (Silver Spring). 2020 04; 28(4):749-755.
    View in: PubMed
    Score: 0.054
  25. Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers. Am Heart J. 2019 06; 212:1-12.
    View in: PubMed
    Score: 0.050
  26. Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). Am Heart J. 2019 06; 212:23-35.
    View in: PubMed
    Score: 0.050
  27. Relationship of visceral and subcutaneous adipose depots to markers of arterial injury and inflammation among individuals with HIV. AIDS. 2019 02 01; 33(2):229-236.
    View in: PubMed
    Score: 0.050
  28. Assessing statin effects on cardiovascular pathways in HIV using a novel proteomics approach: Analysis of data from INTREPID, a randomized controlled trial. EBioMedicine. 2018 Sep; 35:58-66.
    View in: PubMed
    Score: 0.049
  29. Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV. AIDS. 2017 03 27; 31(6):797-806.
    View in: PubMed
    Score: 0.044
  30. Increased FDG uptake in association with reduced extremity fat in HIV patients. Antivir Ther. 2013; 18(2):243-8.
    View in: PubMed
    Score: 0.032
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.